Welcome to our dedicated page for Nextcure SEC filings (Ticker: NXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NextCure, Inc. filings document a clinical-stage oncology issuer's financial reporting, governance, capital structure, and material-event disclosures. Recent Form 8-K reports furnish quarterly and annual results, business update exhibits, Regulation FD materials on ADC programs, officer transition disclosure, a completed private placement of common stock and pre-funded warrants, and an effected reverse stock split.
The company's proxy materials cover annual meeting matters including director elections, auditor ratification, say-on-pay, board governance, and executive compensation for a Delaware corporation with Nasdaq-listed common stock.
NextCure, Inc. filed a current report describing its preliminary year-end liquidity and program updates. The company announced that as of December 31, 2025, it had approximately $41.8 million in cash, cash equivalents and marketable securities, and it currently expects these resources to fund planned operating expenses and capital expenditures into the first half of 2027. This cash figure is unaudited, subject to adjustment, and will be finalized with the company’s consolidated financial statements for 2025.
NextCure also filed a press release and an updated corporate presentation as exhibits, which include updates on its two antibody drug conjugate programs. The report highlights that certain statements, including those about cash runway, development plans, clinical progress and upcoming milestones, are forward-looking and subject to significant risks and uncertainties outlined in the company’s recent annual and quarterly reports.
NextCure, Inc. is registering 2,523,477 shares of common stock for resale by selling stockholders under a shelf prospectus. The shares consist of 708,428 outstanding shares and 1,815,049 shares issuable upon exercise of pre-funded warrants issued in a November 12, 2025 private placement.
Investors in that private placement bought common stock at $8.52 per share and pre-funded warrants at $8.519 per warrant, raising approximately $21.5 million in gross proceeds for NextCure before fees. The warrants are exercisable at $0.001 per share and do not expire.
NextCure will not receive proceeds from any resale of the 2,523,477 shares, but would receive about $1,815 if all pre-funded warrants are exercised, which it expects to use for working capital and general corporate purposes. Shares outstanding were 5,203,299 as of November 25, 2025, assuming full warrant exercise. The company’s common stock trades on Nasdaq under the symbol “NXTC.”
NextCure, Inc. entered into a securities purchase agreement for a private placement of 708,428 shares of common stock at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares at $8.519 per warrant, raising gross proceeds of about $21.5 million before fees. The pre-funded warrants are exercisable immediately and do not expire. NextCure agreed to register the resale of the shares and warrant shares for the participating institutional and accredited investors and to temporarily restrict additional equity issuance, subject to exceptions. The company also announced that, based on its assumptions, its cash, cash equivalents and marketable securities are expected to fund planned operations into the first half of 2027.
NextCure, Inc. (NXTC) filed its Q3 2025 10‑Q reporting continued operating losses and a limited cash position, and raised substantial doubt about its ability to continue as a going concern. Cash, cash equivalents and marketable securities were $29.1 million as of September 30, 2025. Net loss was $8.6 million for the quarter and $46.4 million year‑to‑date, driven primarily by research and development.
R&D expense reflected the Zaiming license, with $17 million recorded as in‑process R&D in 2025. Operating cash outflow was $42.0 million for the nine months. Management expects additional losses and says current liquidity will not fund operations for one year after issuance, indicating the need for near‑term financing or partnerships.
Pipeline updates: SIM0505 (CDH6 ADC) first U.S. patient was dosed in October 2025, with proof‑of‑concept data expected in the first half of 2026. LNCB74 (B7‑H4 ADC) dosed its first patient in January 2025; a protocol amendment allowing higher dose escalation was cleared in November 2025. The company completed a 1‑for‑12 reverse stock split on July 14, 2025, and had 2,679,822 shares outstanding as of October 31, 2025.
NextCure, Inc. filed a current report stating that it released its financial results for the quarter ended September 30, 2025. On November 5, 2025, the company issued a press release with these quarterly results and attached it as Exhibit 99.1. The report clarifies that this press release is being furnished, not filed, which affects how it is treated under securities laws.
NextCure, Inc. (NXTC) Form 3/A reports that Simcere Zaiming, Inc. directly holds 338,636 shares of NextCure common stock. The amendment adds Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Hainan Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Limited, Ren Jinsheng and Tang Renhong as additional reporting persons to the original Form 3 filed by Simcere Zaiming, citing ownership chain and shared voting and investment power. The filing disclaims beneficial ownership except for pecuniary interest and states the amendment only adds reporting persons.
NextCure, Inc. announced that Chief Scientific Officer Solomon Langermann, Ph.D., resigned from his position effective September 1, 2025. His decision to step down is stated as not the result of any disagreement with the company’s operations, policies, or practices.
The board and company publicly thanked Dr. Langermann for his scientific leadership and many contributions during his tenure. The filing does not describe a successor or changes to the company’s scientific programs, focusing instead on the timing and amicable nature of his departure.
NextCure, Inc. has a disclosed 12.7% equity position held through a chain of affiliated entities ultimately controlled by Simcere Pharmaceutical Group Limited. The reporting group states that Simcere Zaiming, Inc. directly holds 338,636 shares of NextCure common stock and that Jiangsu Simcere Zaiming and Hainan Simcere Zaiming may be deemed to beneficially own those same shares through ownership chains. Two individual reporting persons, Jinsheng Ren and Renhong Tang, are disclosed as having shared voting and dispositive power over the 338,636 shares. The ownership percentage is calculated against 2,676,152 shares outstanding as reported by the issuer in its S-3 filing, and the Reporting Persons state the holdings were not acquired to influence control of the issuer.
Simcere Zaiming, Inc. filed a Form 3 reporting initial ownership of 338,636 shares of NextCure, Inc. (NXTC) as of 06/20/2025. The filing states these shares are directly held by Simcere Zaiming and describes the chain of ownership through Jiangsu Zaiming, Hainan Zaiming and Simcere Pharmaceutical Group, naming key executives who may share voting and investment power. The reporting person disclaims beneficial ownership except for pecuniary interest.
NextCure’s Q2-25 10-Q shows a sharp deterioration in liquidity and higher losses driven by a new licensing deal. Cash & equivalents fell to $4.9 m (-82%) and marketable securities to $30.4 m, leaving $35.3 m available versus $68.6 m at YE-24. Management expects this to fund operations only into mid-2026 and discloses substantial doubt about going concern.
Operating expenses jumped 65% YoY to $27.3 m. R&D doubled to $24.1 m, primarily due to a $17 m up-front/I-PR&D charge for the June 2025 SIM0505 ADC license from Zaiming. G&A fell 22% to $3.2 m after a 2024 restructuring. Q2 net loss widened to $26.8 m (-$11.29/sh) from $15.4 m (-$6.61/sh) a year earlier; 1H-loss is $37.8 m.
The company raised only $2 m via a private placement (338.6 k shares at $5.904) classified as mezzanine equity until SEC registration (completed 29-Jul-25). A 1-for-12 reverse split effective 14-Jul-25 restored Nasdaq bid-price compliance, leaving 2.68 m shares outstanding on 4-Aug-25.
Pipeline: Phase 1 B7-H4 ADC LNCB74 cleared cohort 3 and expects back-fill cohorts 2H-25 with PoC read-out 1H-26. SIM0505 IND transferred from partner; first US patient expected 3Q-25. Cost-share ADC collaboration with LigaChem produced a $1 m receivable.
Key balance-sheet items (Jun-25 vs Dec-24):
- Total assets: $47.7 m vs $80.9 m
- Accum. deficit: $417.9 m (was $380.1 m)
- Equity: $29.6 m vs $65.5 m